Voyager Therapeutics entered a license option agreement with Novartis providing target-specific access to Voyager's TRACER AAV capsids for three CNS targets plus options for two more. Voyager received $54M upfront, plus option exercise fees and milestones up to $1.7B and tiered royalties on net sales. In March 2023 Novartis exercised its options to license TRACER-derived capsids for two undisclosed neurologic targets, triggering a $25M option-exercise payment to Voyager, with up to $600M in development, regulatory and commercial milestones for those products plus mid- to high-single-digit tiered royalties.